


**Product Name** : BAY-1816032  
**Cat. No.** : PC-63128  
**CAS No.** : 1891087-61-8  
**Molecular Formula** : C<sub>27</sub>H<sub>24</sub>F<sub>2</sub>N<sub>6</sub>O<sub>4</sub>  
**Molecular Weight** : 534.524  
**Target** : Checkpoint Kinase (Chk)  
**Solubility** : 10 mM in DMSO



2. Siemeister G, et al. *Clin Cancer Res.* 2018 Nov 14. pii: clincanres.0628.2018.

## Biological Activity

BAY-1816032 (BAY1816032) is a highly potent, selective, orally active **BUB1** mitotic checkpoint serine/threonine kinase with IC<sub>50</sub> of 7 nM.

BAY-1816032 displays excellent selectivity on a panel of 395 kinases.

BAY-1816032 abrogates nocodazole-induced Thr-120 phosphorylation of the major BUB1 target protein histone H2A in HeLa cells with IC<sub>50</sub> of 29 nM.

BAY-1816032 induces lagging chromosomes and mitotic delay, inhibits proliferation of various tumor cell lines with mean IC<sub>50</sub> of 1.4 μM.

BAY-1816032 demonstrates synergy or additivity with paclitaxel or docetaxel both in vitro and in vivo.

## References

Gerhard Siemeister, et al. Abstract 287: BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor activity. *AACR*. DOI: 10.1158/1538-7445.

